This company is no longer in business. Investors can get details about any potential exits or failures here.

NowRx

NowRx

Early Stage

Technology-driven, on-demand pharmacy providing free, same-day delivery

Technology-driven, on-demand pharmacy providing free, same-day delivery

Overview

Funding data not publicly available
Platform

SeedInvest

Start Date

04/03/2017

Close Date

07/19/2017

Min. Goal
$100,000
Max. Goal
$1,000,000
Min. Investment

$500

Security Type

Convertible Note

SEC Filing Type

RegCF / RegD 506(c)    Open SEC Filing

Valuation Cap

$6,000,000

Discount

20%

Year Founded

2015

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Location

Mountain View, California

NowRx, with a valuation of $6 million, is raising funds on SeedInvest. It is a pharmacy delivery solution that uses advanced technology to provide free same-day delivery for all prescription needs. NowRx’s on-demand delivery model offers convenience, higher worker productivity, and superior customer experience. The platform has filled thousands of prescriptions and served multiple customers since its launch. Cary Breese and Sumeet Shoekand founded NowRx in February 2015. The current crowdfunding campaign has a minimum target of $100,000 and a maximum target of $1 million. The campaign proceeds will be used for software, sales, and marketing.

Summary Profit and Loss Statement

FY 2016 FY 2015

Revenue

$700,551

$0

COGS

$572,549

$0

Tax

$0

$0

 

 

Net Income

$-583,438

$-247,240

Summary Balance Sheet

FY 2016 FY 2015

Cash

$159,519

$160,765

Accounts Receivable

$178,098

$12,826

Total Assets

$498,583

$308,161

Short-Term Debt

$210,911

$109,551

Long-Term Debt

$1,117,500

$445,000

Total Liabilities

$1,328,411

$554,551

Financials as of: 04/03/2017
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
NowRx 05/19/2022 SeedInvest $275,000,000 $30,006,323 Equity - Preferred Funded RegA+
NowRx 10/04/2021 SeedInvest $275,000,000 $3,635,310 Equity - Preferred Funded Test the Waters / RegA+
NowRx 06/18/2020 SeedInvest $65,000,000 $20,002,878 Equity - Preferred Funded RegA+
NowRx 06/29/2018 SeedInvest $20,000,000 - Equity - Preferred Funded RegA+
NowRx 07/18/2017 SeedInvest $6,000,000 - Convertible Note Funded RegCF / RegD 506(c)
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
NowRx on SeedInvest 2017
Platform: SeedInvest
Security Type: Convertible Note
Valuation: $6,000,000

Follow company

Follow NowRx on SeedInvest 2017

Buy NowRx's Deal Report

Warning: according to the close date for this deal, NowRx may no longer be accepting investments.

NowRx Deal Report

Get KingsCrowd’s comprehensive report on NowRx including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether NowRx is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the NowRx deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge